Vantictumab (OMP-18R5) is a humanized anti-FZD1/2/5/7/8 monoclonal antibody that inhibits Wnt pathway signaling and is used in research studies for the treatment of metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
Purity:
97.70%
CAS Number:
[1345009-45-1]
Target:
Wnt/beta-catenin
* VAT and and shipping costs not included. Errors and price changes excepted